Two Clinical Trials Underway at Methodist Neuroscience Institute
The Methodist University Hospital Neuroscience Institute is dedicated to maintaining a practical balance of teaching, research and patient care under one roof to offer the maximum benefit to patients. Two clinical studies related to Glioblastoma Multiforme are currently open and seeking participation at MUH-NI.
- Cilengitide for subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter–a multicenter, open-label, controlled phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone (CENTRIC) (L. Madison Michael, M.D., Principle Investigator)
- BIBW 2992 with or without daily temozolomide in the treatment of patients with recurrent malignant glioma (L. Madison Michael, M.D., Principle Investigator)
For more information or to make a referral, contact Cathy Maranise, R.N., Clinical Research Coordinator at 901.259.5314.